MetaCap

AgomAb Therapeutics NV (AGMB) vs Precision BioSciences (DTIL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precision BioSciences is the larger company by market cap ($282.5 million vs $268.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGMB-62.80%DTIL+94.74%
+191%+58%-75%
Feb 6, 20261 yearNov 20, 2026
AGMB-62.80%DTIL+94.74%
+191%+58%-75%
Feb 2, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGMB versus DTIL key metrics
MetricAGMBDTIL
Share price$5.45$7.40
Market cap$268.40M$282.46M
1-day change-3.02%+7.09%
YTD return—+77.88%
1-year return—+48.00%
5-year return—-97.23%
P/E ratio (TTM)—29.60
EPS (TTM)$-2.08$0.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$34.26M
Revenue growth (YoY)—-50.12%
Net income (latest FY)—$-45.72M
Operating margin—-152.19%
Net margin—-133.45%
52-week high$17.82$11.29
52-week low$5.39$3.53
Distance from 52-week high-69.42%-34.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+591.19%+297.30%
Average volume208.99K319.79K
Shares outstanding49.25M38.17M
Employees6269
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AgomAb Therapeutics NV

AGMB stock →

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees

About Precision BioSciences

DTIL stock →

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees

AGMB vs DTIL FAQ

Which is bigger, AgomAb Therapeutics NV or Precision BioSciences?

Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $268.40M for AgomAb Therapeutics NV (AGMB).

Are AgomAb Therapeutics NV and Precision BioSciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons